Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Medartis

Health Tech & Medtech · Basel, Switzerland · Founded 1997 · IPO 2018 Unicorn

Promotes technologies and solutions for osteosynthesis in the fields of cranio-maxillofacial surgery as well as upper and lower extremities

Valuation
$990M
Market cap · May/2026
Revenue
$247M
Latest reported FY
EBITDA
$56M
Latest reported FY

Global footprint

Where Medartis has talent and traffic

Workforce by country
21 countries with
team presence
🇨🇭 Switzerland34.7%
🇩🇪 Germany11.8%
🇧🇷 Brazil11.1%
🇺🇸 United States8%
🇫🇷 France6.6%
Top 5 of 21 shown

Patent intelligence

$32M patent portfolio · 79 active families

Estimated portfolio value
$32M
3.2% of market cap · 15.9× smaller than top peer Insulet ($502M)
79 active patent families
Where Medartis innovates Biomedical engineeringAnatomySurgeryIliac screwGeneral surgery

Where Medartis concentrates vs peers

Each axis is a top-10 topic across Medartis and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Medartis's 6 investments and acquisitions.

Every disclosed deal where Medartis appeared as a backer or acquirer, 2017–2026. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

6 deals across Medartis's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Medartis deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Medartis's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        6 of 6 deals

        Market sentiment

        What the market is saying about Medartis

        An AI-synthesized read of the highest-engagement posts about Medartis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Medartis on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.